Kornimate/medical-research-clean huggingface dataset:
chronic heart failure - cheyne stokes respiration - cs2 (3c-study)

Conditions: Heart Failure; Cheyne Stokes Respiration

Summary: an investigation where patients with chronic heart failure and cheyne stokes respiration, treated with adapitve servo ventilator, will improve their cardiac function and quality of life.

chronic heart failure (hf) is one of the most important public health problems in cardiovascular medicine. several patients with chronic heart failure also has cheyne stokes respiration pattern. earlier studies have shown that this respiration pattern improves with adaptive servo ventilator. we wish to investigate wether this leads to improved cardiac function.

Eligibility criteria:
inclusion criteria: * ejection fraction \<40% * nyha class iii-iv * optimized therapy with drugs * cheyne stokes respiration pattern \> 25% while sleeping * age \< 85 years * clinical stability the last month before inclusion. exclusion criteria: * cabg less then 6 months ago * pci treatment less then 3 months ago * unstable angina pectoris * acute coronary syndrome less then 3 months ago * stroke less then 6 weeks ago * thoracal myopathy * advanced copd

Keywords: heart failure cheyne stokes respiration adaptive servo ventilator
maximizing outcomes for preschoolers with developmental language disorders

Conditions: Developmental Language Disorder

Summary: the objective of the proposed study is to evaluate the efficacy of the enhanced milieu teaching-sentence focus (emt-sf) intervention, implemented by caregivers and interventionists, relative to a control condition enrolling 108 30-month-old children and their caregivers. the central hypothesis is that intervention will result in better overall child language skills at 49 months of age.

a multi-site, phase 2, randomized clinical trial will be used to determine whether communication support strategies are effective for improving language outcomes in children with emergent developmental language disorder. at study entry, 108 children with emergent developmental language disorder (dld) at 30 months of age will be randomly assigned 1:1 to either the emt-sf treatment condition or a business as usual (bau) control group. the control group is necessary to determine the efficacy of the emt-sf intervention. the emt-sf group is necessary to evaluate the effects of systematically teaching caregivers to use these strategies. because all children in the study have language delays that will make them eligible to receive the early intervention services through the state early intervention program, children in both experimental conditions will receive state-provided community-based intervention according to their individualized family service plan - the current standard of care or from private speech language therapy providers. children in the emt-sf condition will receive an additional 18 months of interventionist plus caregiver-implemented intervention sessions. children in both groups will be assessed at the start of the study and every 3 months until the child is 49 months old. the goal is to enroll all children at 30 months of age and provide a minimum of 60 of the planned 66 sessions of intervention to each child in the treatment condition; however, variability in age at study entry (e.g., 30 months), intervention dosage, and number of assessment data points will be addressed in the statistical analysis.

Eligibility criteria:
inclusion criteria: * parent or caregiver (mother, father, grandparent) willing to participate in caregiver training over the full 18 months of the study * normal non-verbal cognitive abilities * receptive and expressive language delay: * english as the only language spoken to the child in the home * provision of signed and dated informed consent form * attempts to imitate 10 words exclusion criteria: * diagnosis of a neurodevelopmental disability other than dld (e.g., down syndrome, asd, intellectual disability) * caregiver report of a major medical condition (e.g., seizures, cancer, stroke, traumatic head injury, cleft lip/palate, cerebral palsy, legally blind, any genetic diagnosis associated - - caregiver report of preterm birth (i.e., \< 37 weeks gestation) * caregiver report of hearing impairment or audiological testing indicating hearing thresholds \> 20db * caregiver report or direct observation of any problems chewing, sucking through a straw, or blowing bubbles.
the use of 2% chlorhexidine gluconate impregnated cloth bathing in preoperative skin preparation

Conditions: Surgical Site Infection

Summary: to compare the use of towels impregnated with 2% chlorhexidine gluconate in the traditional preoperative bath with 2% chlorhexidine gluconate in preventing the occurrence of surgical site infection among patients undergoing potentially contaminated elective surgery.

this is a pilot randomized controlled clinical trial, composed of patients submitted to potentially contaminated elective surgeries, randomly assigned to an intervention group, consisting of those who used towels impregnated with pre-operative chg 2% and control group, composed of by the pre-operative bath with 2% conventional / liquid chg. both used the products the night before and the morning of surgery and received verbal and written guidance.

Eligibility criteria:
inclusion criteria: * 18 years of age or over * literate * undergoing potentially contaminated elective surgeries * admitted on the day before the surgical treatment or in the triple three-day hospital stay prior to surgery, without an infectious or otherwise infected process * correctly follow the instructions for the use of towels impregnated with chlorhexidine gluconate 2% * follow the instructions for the use of chlorhexidine gluconate 2% exclusion criteria: * submitted to previous surgeries, in a period of less than thirty days, or ninety days in the case of a prosthesis implant * present skin lesions or known allergy to chlorhexidine gluconate 2% * patients submitted to videolaparoscopic surgeries and vaginal surgeries * patients who had daily use of products containing antiseptics (creams and / or liquid or bar soaps containing chg, triclosan or similar) in their daily activity; or who had used antibiotics or similar drugs two weeks before and during the period of data collection.
program aactive: african americans coming together to increase vital exercise

Conditions: Type 2 Diabetes; Depression

Summary: program aactive will enroll 80 african american/black men with type 2 diabetes and depression. participants will be randomized to either the intervention arm or the control arm. participants in the intervention arm will receive counseling (cognitive behavioral therapy) and physical activity sessions over 12 weeks. counseling and physical activity sessions will take place via a video conferencing platform. there will also be 3 in-person health assessments including baseline, at 12-weeks and 3-month follow up. the investigators are interested in seeing if physical activity and counseling improve a1c outcomes and depression symptoms for participants.

participants will be randomized to the program aactive intervention group or an enhanced usual care (euc) group. the intervention group will receive 10 sessions of cognitive behavioral therapy (cbt) and 6 physical activity sessions over the 12-week period. all program aactive cbt sessions and exercise sessions will run concurrently and take place virtually.

Eligibility criteria:
inclusion criteria: * african american/black males, ambulatory status, diagnosed with type 2 diabetes for one year duration or longer, phq-9 score \>=15 with no self-reported psychotic symptoms, live in the wayne or washtenaw counties, have reliable transportation to in-person events, have reliable access to internet and a device that supports video calls. exclusion criteria: * stage 2 hypertension as defined by jncviii, recent cardiac events, recent laser surgery for proliferative retinopathy, history of stroke, lower limb amputation, peripheral neuropathy, aortic stenosis or other sever valvular heart disease, atrial fibrillation, severe copd (e.g., basal oxygen), class iii or iv heart failure or medical instability. participants who are currently receiving psychotherapy services for the treatment of depression from a mental health care provider will be excluded while participants who are currently receiving only medication management from as psychiatrist will be included.
the oral microbiota is associated with autoimmune thyroiditis

Conditions: Microbiota

Summary: autoimmune thyroiditis (aitd) mainly includes hashimoto's thyroiditis (ht) and grave's disease (gd). studies have shown that autoimmune thyroiditis is closely related to microbial disorders such as autoimmune thyroiditis however, there is no report on the relationship between oral microecology and autoimmune thyroiditis. therefore, our group will study the correlation between oral microbiota and aitd.

autoimmune thyroiditis (aitd) mainly includes hashimoto's thyroiditis (ht) and grave's disease (gd). studies have shown that autoimmune thyroiditis is closely related to microbiological disorders. intestinal microelements both ecology and oral microecology belong to the category of microorganisms. it has been reported in the literature that intestinal microecology occurs disorder of autoimmune thyroiditis. however, there is no report on the correlation between oral microecology and autoimmune thyroiditis. when oral microbe flora when the immune system is disrupted, the immune balance is broken, the immune system is over-active, and the autoimmune disease (aid) is lost to the autoantigens and non-pathogenic commensal microbial flora antigens, including rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematosus, inflammatory bowel disease, and allergic diseases. however, the association between oral microbial flora and aitd remains unclear. . therefore, the research group will carry out the correlation between oral microbial flora and aitd.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years * gd was clinical diagnosed and thyroid function returned to normal * ht was clinical diagnosed and thyroid function is normal. exclusion criteria: * pregnancy * lactation * cigarette smoking * alcohol addiction * hypertension * diabetes mellitus * lipid dysregulation * bmi \> 27 * recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or chinese herbal medicine * history of disease with an autoimmune component, such as ms, rheumatoid arthritis, ibs, or ibd * history of malignancy or any gastrointestinal tract surgery

Keywords: oral microbiota 16s rrna gene graves' disease methimazole propylthiouracil hashimoto's thyroiditis
bonviva(ibandronate) pms(post-marketing surveillance )

Conditions: Osteoporosis

Summary: this is an open label, multi-centre, non-interventional post-marketing surveillance.

this is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ibandronate administered in korean patients according to the prescribing information.

Eligibility criteria:
inclusion criteria: all subjects must satisfy the following criteria at study entry: 1. subjects diagnosed with osteoporosis in postmenopausal women. 2. subjects who the investigator believes that they can and will comply with the requirements of the protocol 3. subjects with no experience of treatment using ibandronate. 4. subjects who are administered of ibandronate in normal prescription use exclusion criteria: considering the nature of this non-interventional pms study, there is no strict exclusion criteria set up. the doctors participating this study to enrol the subjects prescribed with ibandronate following the locally approved prescribing information. the following criteria should be checked at the time of study entry. according to contraindication on the prescribing information, ibandronate should not be administered to the following patients: 1. patients with known hypersensitivity to ibandronate or to any of its excipients 2. uncorrected hypocalcemia 3. inability to stand or sit upright for at least 60 minutes

Keywords: osteoporosis ibandronate
exploratory study of dha in systemic lupus erythematosus patients

Conditions: Systemic Lupus Erythematosus

Summary: the primary objective of the study is to assess the efficacy of dha in patients with sle.

this is a phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of four oral treatment regimens of dha versus placebo while taking standard of care (soc) treatment with corticosteroids in adult subjects with systemic lupus erythematosus (sle).

Eligibility criteria:
key inclusion criteria: 1. fulfill at least 4 diagnostic criteria for sle defined by american college of rheumatology; 2. positive antinuclear antibodies (ana); 3. activity index (sledai) score must be 6-11 points, inclusive; 4. stable dose of prednisone (\<30mg/d) for at least one month ; 5. active mild to moderate sle activity as demonstrated by british isles lupus assessment group index (bilag); 6. males or females between 18 and 65 years old; 7. weight of 45 kg or greater. key exclusion criteria: 1. active severe lupus as defined by bilag index level a or two or more of level b in any body system/organ; 2. subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections; 3. presence of active central nervous system (cns) disease requiring treatment; 4. subjects with active, severe sle disease activity which involves the renal system; 5. substance abuse or dependence; 6. history of malignant cancer within the last 5 years; 7. subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion; 8. subjects received any live vaccination within the 30 days prior to visit 2; 9. subjects received intravenous immunoglobulin (ivig) or,plasmapheresis,or high dose prednisone or equivalent (\> 100 mg/day) within 90 days prior to visit 2; 10. subjects who have had therapy with cyclophosphamide within 180 days prior to visit 2 .

Keywords: dihydroartemisinin;systemic lupus erythematosus
wearable devices for secondary prevention of ischemic stroke

Conditions: Stroke, Ischemic; Atrial Fibrillation

Summary: ischemic stroke is an important cause of death and disability in western countries. different risk factors have been identified such as hypertension, diabetes, dyslipidemia, smoke, atrial fibrillation, obesity, and sedentary. the aim of this study is to evaluate the feasibility of an approach based on the use of wearable devices for the identification and reduction of risk factors in patients with previous history of ischemic stroke or transient ischemic attack.


Eligibility criteria:
inclusion criteria: * age greater than or equal 50 years * recent transient ischemic attack or minor stroke exclusion criteria: * patients with significant cognitive impairment * patients dependent in the instrumental activities of daily life * patients not able to respect the frequency of monitoring program * patients with history of atrial fibrillation
investigation of subsequent and co-infections associated with sars-cov-2 (covid-19)

Conditions: COVID-19

Summary: multicenter retrospective chart review of patients admitted to any of the four methodist health system hospitals

multicenter retrospective chart review of patients admitted to any of the four methodist health system hospitals (methodist richardson, methodist mansfield, methodist charlton, or methodist dallas) between february 1 and april 30, 2020. all study center utilize epic ® electronic health record (verona, wisconsin; www.epic.com) for which all data will be extracted from.

Eligibility criteria:
inclusion criteria: * patients admitted to methodist richardson, methodist mansfield, methodist charlton, or methodist dallas medical centers between february 1, 2020 and april 30, 2020 * \>18 years old * positive sars-cov-2 (covid-19) pcr test exclusion criteria: * outpatient or emergency department visit * not admitted to an inpatient or observation status for \>24 hours
the effect of stabilization exercises after radiofrequency lumbar facet denervation

Conditions: Low Back Pain; Facet Joint Pain; Radiofrequency Denervation; Pain; Disability Physical

Summary: a gap of knowledge exists on the understanding of the acute effects of stabilization exercises on pain, disability and physical performance when applied after radiofrequency denervation. therefore, the main objective of this study is to show the effects of stabilization exercises when started in acute period and also reduce the frequency of recurrence low back pain of patients with fjs after radiofrequency denervation.

lumbar facet joint syndrome has been described as a potential cause of low back pain and affects an estimated 4% to 8% of those low back pain patients without neurological deficits or radiographic evidence of lumbar spine disease. the levels of physical performance and functional disability of the patients with lumbar fjs are affected because of the chronicity of the pain. radiofrequency denervation (rfd) is one of the therapautic procedures are used most commonly in treatment of facet joint syndrome. numerous placebo-controlled trials have examined lumbar facet pain and demonstrated that rfd yields positive results in lumbar pain in properly selected patients. the lumbar stabilization exercise is based on the control of the local muscle system (multifidus, transversus abdominis, diaphragm and pelvic floor muscles) responsible for ensuring segmental stability of the vertebral colon in recent years. in the clinical trials, stabilization exercises have been shown to reduce pain, improves physical performance and prevent the recurrent low back pain by strengthing of muscles supporting the vertebral colon. therefore, the main objective of this study is to show the effects of stabilization exercises when started in acute period and also reduce the frequency of recurrence low back pain of patients with fjs after radiofrequency denervation.

Eligibility criteria:
inclusion criteria: * age older than 45 year, failure to improve with conservative treatment, limited functions and daily life, pain exacerbated by rest, sitting or standing exclusion criteria: * previous surgical intervention in the spine or hip, previous local injection to the lumbar spine facet joint, current treatment with a narcotic drug, impairment of cognition or speech
using combined eeg and non-invasive brain stimulation to examine and improve reward functioning in opioid use disorder

Conditions: Opioid-use Disorder

Summary: the primary aims of this study are to identify impaired cognitive control in opioid use disorder (oud) and subsequently to examine the effects of transcranial magnetic stimulation (tms) on reward processing, as measured by the reward positivity (an electrophysiological signal) in people with oud. to this end, the investigators will adopt a randomized sham-controlled trial to evaluate the efficacy of ri-tms on cognitive control in oud. the investigators hypothesize that ri-tms will be successful in modulating the reward positivity in opioid users in the active tms condition.

the design is primarily a randomized control-trial design, comparing the effects of placebo (sham) and active tms stimulation on reward processing across two groups of participants - healthy controls and opioid users. participants will be asked to engage in a virtual t-maze task, a reward-based choice task that elicits robust reward positivities. during this task participants will receive simultaneous eeg/tms, while they engage in the virtual t-maze decision making task, used in our previous reward positivity studies on suds. erps will be recorded throughout the t-maze task, and the reward positivity will be measured as the difference in maximum amplitude between reward and no-reward feedback conditions. the tms coil will be positioned using a an adept viper s850 robotic arm (smartmove, ant neuro, enschede, the netherlands), providing precise targeting of the predetermined left dorsolateral prefrontal (dlpfc) coordinate (\< 10 mm from the scalp, orientated at a 45º angle). participants in the active tms condition will receive rtms pulses throughout the duration of the t-maze task, with a maximum of 2000 pulses delivered to each participant. identical parameters will be applied to the sham group with the exception that the tms coil will be flipped 180º to mimic auditory stimulation.

Eligibility criteria:
inclusion criteria: * native english speakers * males and females aged 18-55 years old * ability to provide informed written or verbal consent * opioid dependent individuals (according to the alcohol, smoking and substance involvement screening test opioid dependence score), or * healthy controls with no history of significant substance use exclusion criteria: * un-correctable visual impairment * uninterruptable central nervous system medication * tms contraindications (e.g., pregnancy, braces, history of seizures, metal implants). * history of neurological or psychiatric illness * diagnosed learning disability * history of significant head injury (loss of consciousness for more than five minutes) * substance abuse (participants who score above 39.5 on the global continuum of substance risk scale of the alcohol, smoking and substance involvement screening test - controls only) * use of psychoactive or vasoactive medications

Keywords: transcranial magnetic stimulation reward processing cognitive control
the use of isatidis root and forsythia oral liquid for the treatment of mild cases of covid-19: a trial clinical study

Conditions: Treatment of Mild Cases of COVID-19

Summary: this study has significant implications for research, as it provides a basis for further studies on the antiviral effects of lglq oral liquid, encouraging more extensive clinical studies in larger populations and diverse age groups to validate these findings. for medical practice, the findings suggest that lglq can be considered an alternative treatment option for mild cases of covid-19, especially in managing symptoms like fatigue, potentially broadening the range of effective treatments available to healthcare practitioners. in terms of policy, the demonstrated efficacy of lglq could lead to its inclusion in treatment guidelines for covid-19 and other viral infections, fostering a more integrated approach combining western medicine and traditional chinese medicine in the global fight against pandemics. the insights from this study might prompt health policymakers to reassess the potential of herbal formulations in managing and treating infectious diseases and consider them in the development of future healthcare strategies and policies.


Eligibility criteria:
inclusion criteria: * the diagnosis of sars-cov-2 infection confirmed by quantitative polymerase chain reaction (qpcr) test * aged 18 years or older * patients received more than 2 doses of sars-cov-2 vaccine * asymptomatic or mild at the time of hospitalization exclusion criteria: * patients with malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, neurological diseases, endocrine diseases and other serious diseases may affect the patient's participation in the trial or affect the results of the study * pregnant women, lactating mothers; allergic conditions * allergic to the known components of the drug * patients vaccinated with vaccines less than 1 shot * patient does not agree to participate in this study